IDH1 and central nervous system cancer: While out of the scope of this preliminary, retrospective analysis, a larger, multi-institutional cohort analysis or prospective study is needed to further characterize outcomes in IDH1/2 mutant grade 2/3 gliomas treated with LITT and further elucidate its effects on PFS compared to both open surgical resection and IDH1/2 wild-type gliomas; this will be the focus of future work.